Question to the Department of Health and Social Care:

To ask Her Majesty's Government, further to the approval of Evusheld by the Medicine and Healthcare products Regulatory Agency on 17 March, when they plan to announce their policy on the provision of Evusheld; and if they are not yet ready to make an announcement, what progress they have made on developing the clinical commissioning policy for Evusheld.

The UK Health Security Agency has tested the efficacy of Evusheld against the Omicron variants and initial data for BA.1 and BA.2 has been shared with AstraZeneca. The Department and the National Health Service are identifying appropriate patient cohorts and approaches to the potential deployment of pre-exposure prophylaxis. We have asked clinicians to advise on the most appropriate option for the NHS in line with all available data, the public health situation and other treatments available. However, we are unable to confirm a specific timetable for decisions for a commissioning policy for Evusheld.